The case for & against
Bull & Bear analysis
NeuroPace, Inc. (NASDAQ: NPCE) is an emerging company in the medical technology sector, specializing in responsive neurostimulation systems for treating epilepsy. The company is known for its innovative Responsive Neurostimulator (RNS) system, which adapts to abnormal brain activity to reduce seizure frequency. Positioned at the intersection of neuromodulation and advanced data analytics, NeuroPace aims to expand its market penetration through increased adoption in existing centers and strategic advancements in clinical evidence and product innovation.
Bull says
- ↑Q1 2026 revenue $22.1M (+8% YoY); full-year guide raised to $99–101M.
- ↑RNS system gross margin strong at 82.5% supports unit economics.
- ↑Seizure ID AI tool rollout to enhance clinician workflows.
- ↑Commercial team expansion, doubling nurse navigators to drive adoption.
- ↑Productive FDA talks on IGE indication; approval expected mid-2026.
- ↑Analysts maintain Moderate Buy with ~$18.83 target on positive revisions.
Bear says
- ↓Q1 net loss $6.7M and adjusted EBITDA loss $3.3M highlight cash burn.
- ↓Operating expenses climbed to $21.5M vs. $54.8M cash, pressuring runway.
- ↓Nautilus PMA supplement for IGE faces potential FDA delays.
- ↓Sales rely heavily on Level Four epilepsy centers; any disruption cuts revenue.
- ↓Competitive neuromodulation advances threaten market share gains.
- ↓Weak profitability and liquidity factors point to financial vulnerability.
Investment themes with NPCE
Clinical instruments and devices powering patient care
Devices and instruments for medical treatment
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We delivered total revenue of 22.1 million dollars in the quarter and excluding dixie medical we delivered 22 million in revenue representing eight percent year-over-year growth with rns system revenue of 21.7 million dollars.
- Importantly, the underlying fundamentals of the business remain solid as we reached new all-time highs in active prescribers accounts and patient pipeline during the quarter.
- We believe this is important not only for continued penetration of the adult focal population, but also for establishing referral pathways that will be relevant as we potentially expand into IGE.
Bear points
- Total stock-based compensation in the quarter was $2.3 million, with $2.1 million included in operating expenses and the balance in cost of goods.
- GAAP net loss was $6.7 million for Q1 2026, compared with net loss of $6.6 million in the prior year quarter, which included Dixie Medical in both periods.